Phase 3Recruiting
Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion (INTEGRAL)
- Sponsor
- Texas Cardiac Arrhythmia Research Foundation (Academic or other)
- Enrolment
- 234 planned
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- Half-Dose of novel OAC; Low-dose ASA
- Ages
- adults, older adults
- Registry
- NCT07840365
From the registry
This randomized study was designed to compare two antithrombotic regimens (long-term half-dose apixaban vs long-term aspirin after 45-days of full-dose apixaban) after successful Watchman implantation.
Primary outcomes
- Composite endpoint of DRT, TE and major bleeding events